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Abstract
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disorder characterized by broad clinical manifestations
including cardiovascular and renal complications with periodic disease flares and significant morbidity and mortality. One of
the main contributing factors to the pathology of SLE is the accumulation and impaired clearance of immune complexes of
which the principle components are host auto-antigens and antibodies. The contribution of host lipids to the formation of
these autoimmune complexes remains poorly defined. The aim of the present study was to identify and analyze candidate
lipid autoantigens and their corresponding anti–lipid antibody responses in a well-defined SLE patient cohort using a
combination of immunological and biophysical techniques. Disease monitoring in the SLE cohort was undertaken with serial
British Isles Lupus Assessment Group (BILAG) scoring. Correlations between specific lipid/anti-lipid responses were
investigated as disease activity developed from active flares to quiescent during a follow up period. We report a significant
negative correlation between anti-lipid antibodies for 24S-hydroxycholesterol, cardiolipin and phosphatidylserine with SLE
disease activity. Taken together, these data suggest that lipid autoantigens represent a new family of biomarkers that can
be employed to monitor disease activity plus the efficacy of therapeutic intervention in SLE.
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Introduction
Systemic Lupus Erythematosus (SLE) is a chronic inflammatory
autoimmune disease found predominantly in women. Complex
interactions amongst immune, genetic, environmental and hor-
monal factors have been implicated in SLE susceptibility and
pathogenesis [1]. Numerous mouse and human studies have
implicated dysfunctional cellular and immune components
including autoimmune T and B lymphocytes [2,3,4]; elevated
levels of pro- inflammatory cytokines [5]; formation of antinuclear
antibodies [6]; accumulation and impaired clearance of post-
apoptotic cell remnants [7,8] or failure of FccR-mediated
clearance of immune complexes [9] in the pathology of Systemic
Lupus Erythematosus.
The role of lipids and anti-lipid responses in Systemic Lupus
Erythematosus and other autoimmune diseases remains poorly
defined in comparison to proteins and genetic factors based on the
technical challenges inherent in their analysis. A summary of
studies linking oxysterols, phospholipids and prostaglandin deriv-
atives with autoimmune, degenerative and age-related diseases
including SLE is provided in Table 1. Thus there is a requirement
for a broader and more detailed analysis of the role of lipids in
these diseases.
Oxysterols represent the family of host lipids most strongly
implicated in autoimmune conditions (Table 1). These are
oxygenated derivatives of cholesterol that are intermediates in
the cholesterol excretion pathway [10]. Cholesterol oxidation is
either through attack by reactive oxygen species (ROS) that
oxygenate the sterol ring at the C7-position or by enzymatic
hydroxylation of cholesterol side-chains that generate 24S-, 25-
and 27-hydroxycholesterol respectively [11]. 24S-hydroxycholes-
terol is specifically generated in the central nervous system [12–13]
and plasma levels of this lipid have been implicated in diseases
linked to CNS inflammation including Alzheimer’s and Vascular
dementia [14].
Elevated plasma levels of 24S-hydroxycholesterol was reported
in Multiple Sclerosis (MS) patients with positive cranial MRI scans
indicating an acute inflammatory episode of demyelination [15].
Oxidized phosphatidylcholine and their corresponding autoanti-
bodies have also been implicated in MS [16]. Other lipid markers
including F(2)-isoprostanes, 7-b-hydroxycholesterol, 7-ketocholes-
terol and 27-hydroxycholesterol have been linked to Parkinson’s
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disease [17]. 7-ketocholesterol may also be involved in the
pathophysiology of atherosclerosis where it is suspected of
inducing apoptosis in the cells of the vascular wall including
monocytes/macrophages [18]. This lipid is also known to be
related to oxidized-LDL-mediated cytotoxicity [19]. 7-b hydro-
xycholesterol is proposed to promote human NK cell death and
may also be involved in atherosclerosis [20]. This study focuses on
the role of oxidized lipids and anti-lipid responses in Systemic
Lupus Erythematosus (SLE).
Materials and Methods
Patients
The patient cohort employed was composed of individuals
referred to Addenbrooke’s Hospital, Cambridge, UK between
2004 and 2008. All patients provided written informed consent
and ethical approval was obtained from the Cambridge Local
Research Ethics Committee (Ref: 04/023). Blood was collected at
two time points: the moment of disease [21] - flare; and during the
follow-up period. Follow-up was defined as the period between 3-
months and 12-months post therapy. Disease monitoring was
undertaken with serial BILAG scoring [22]. All patients were
enrolled with active disease with an average BILAG score of 16.01
prior to treatment. Patients on treatment entered clinical remission
and the average BILAG score in the follow up period was reduced
to 2.4+/22.1. For all patients, a full haematological, biochemical
and immunological profiling was done [21]. BILAG scores for 3
time-points and clinical data for patients with flare are included
(Supplementary table). Thirteen paired SLE patients’ samples
were used to analyze changes in lipid and anti-lipid IgG levels
between the flare and follow-up period (between 3–12 months
post-therapy). Twenty patients with flare (including 13 previously
mentioned patients) were used for the correlation analysis.
Blood Processing
Blood was collected in EDTA tubes and peripheral blood
mononuclear cells (PBMC) separated on Ficoll-Paque PLUS
gradient (GE Healthcare, Sweden). Plasma was stored at 280uC
prior to use.
Lipid Standards and Chemicals
Phosphatidylcholine, oxidized phosphatidylcholine, cardiolipin,
phosphatidylserine, were obtained from Avanti Polar Lipids
(Alabaster, AL, USA). 7-ketocholesterol, 7 alpha-hydroxycholes-
terol, 7 beta-hydroxycholesterol, and cholesterol which were
purchased from Sigma (St. Louis, MO, USA), 24S-hydroxycho-
lesterol was obtained from Steraloids (Newport, RI, USA). 7-a-
hydroxycholesterol-d7, 7-b-hydroxycholesterol-d7, 26 (27)-OH
cholesterol-d5, 24S-hydroxycholesterol-d6, 7-ketocholesterol-d7,
Table 1. A summary of reported lipids and anti-lipid antibodies involved in autoimmune, degenerative and age-related diseases.
Pathologies
Organ
involved
Associated oxidized
lipid/anti-lipid Ab
Origin of oxidized
lipid
Method of
detection Reference
Alzheimer disease, vascular
demented patients
CNS 24S-hydroxycholesterol Plasma ID-MS [14]
Alzheimer disease CNS 24S-hydroxycholesterol Plasma, cerebrospinal
fluid
ID-MS [49]
Multiple sclerosis CNS 24S-hydroxycholesterol Plasma, cerebrospinal
fluid
ID-MS [15]
Alzheimer disease CNS 27-hydroxycholesterol Brain tissue GC-MS [50]
Hereditary spastic paresis CNS 27-hydroxycholesterol, 25-hydroxycholesterol Plasma, cerebrospinal
fluid
ID-MS [51]
Atherosclerosis Cardiovascular 27-hydroxycholesterol, 25-hydroxycholesterol,
7b- hydroxycholesterol
Plasma HP-LC [52]
Parkinson disease CNS F(2)-isoprostanes, hydroxyeicosatetraenoic
acid products, 7b- hydroxycholesterol, 27-
hydroxycholesterol, 7-ketocholesterol,
neuroprostanes(F(4)NPs)
Plasma GC-MS [17]
Multiple sclerosis CNS 7-ketocholesterol Serum, CSF ID-MS [53]
Multiple sclerosis CNS Oxidized phosphatidylcholine (OxPC)
Anti-OxPC (T15 Idiotype) antibodies
Brain extracts, CSF Western blotting, [16]
SLE Different organ
systems
Anti-cardiolipin Ab Serum ELISA [54]
Immunoglobulin A deficiency Different organ
systems
Anti-cardiolipin Ab Serum ELISA [55]
Antiphospholipid syndrome Different organ
systems
Anti-cardiolipin Ab Serum ELISA [56]
Systemic Lupus Erythematosus Different organ
systems
15-F2t-IsoP Serum ELISA [57]
Systemic Lupus Erythematosus Different organ
systems
15-F2t-IsoP Plasma GC-MS [58]
Systemic Lupus Erythematosus;
Antiphospholipid syndrome
Cardiovascular
system
Anti-phosphatidylserine Ab,
Anti-cardiolipin Ab
Plasma ELISA [59]
Alzheimer disease CNS 24S-hydroxycholesterol Plasma LC-MS [60]
doi:10.1371/journal.pone.0055639.t001
Anti-Lipid Responses in SLE
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lathosterol, and lathosterol-d4 were purchased from CDN Isotopes
(Quebec, Canada). Arachidonic acid, arachidonic acid-d8, 8-Iso-
PGF2a (8-iso-prostaglandin F2a or 15-F2t-IsoP or iPF2a-III), 8-iso-
PGF2a-d4, 8-F2t-IsoP-d4 (iPF2a-IV or 5S,9a,11a,-trihydroxy-
1a,1b,1g-trihomo-18,19,20-trinor-8b-prosta-2Z,6E-dien-1-oic ac-
id) and 5-F2t-IsoP (iPF2a-VI-d4 or 5S,9a,11a,-trihydroxy-(8b)-
prosta-6E,14Z-dien-1-oic acid) were purchased from Cayman
Chemical (Ann Arbor, MI USA). All solvents used were HPLC
grade.
Enzyme-linked Immunosorbent Assay (ELISA) and Lipid
Quantification
Maxi-sorp plates (NUNC, Denmark) were coated with 5 ug/ml
of lipids in EtOH evaporated for 2 hrs at RT. Plates were blocked
with 0.8% collagen in PBS (Sigma-Aldrich, USA). Anti-lipid IgG
responses were detected using goat-anti human IgG antibody
conjugated with horseradish peroxidase (HRP) (Thermo Scientific
Pierce, USA). TMB substrate (BD OptEIATM, BD Biosciences)
was employed for 15 mins and colour development assayed at
450 nm using a Perkin-Elmer Victor3V plate reader.
Lipid Extraction and Gas Chromatography-mass
Spectrometry (GC- MS)
Lipids were extracted using a modified Folch method and
hydrolysed in methanolic KOH [23]. COPs and F2-Isoprostanes
were then purified into 2 separate fractions by solid phase
extraction on mixed mode anion exchange columns, dried under a
stream of nitrogen, derivatised and injected onto an Agilent 5973/
6890 GC-MS system as described previously [24]. Briefly,
cholesterol oxidative products (COPs) were derivatised to generate
their trimethyl silyl ether derivatives and analysed in the EI
(electron ionization) mode. F2-isoprostanes were derivatised to
form their pentafluorobenzyl (PFB) ester, trimethyl silyl ether
derivatives and analysed in the NCI (negative chemical ionization)
mode. Quantification was achieved by relating peak area of
samples with respective deuterated internal standards according to
the previously published method [25]. 8-Iso-PGF2a and 5-F2t-IsoP
F2-isoprostane isomers co-eluted and were measured together as a
single peak.
Lipid Extraction and Liquid Chromatography – Mass
Spectrometry (LC – MS)
Phospholipids were extracted according to a modified protocol
of Bligh and Dyer, 1959 [26]. Synthetic lipids obtained from
Avanti Polar Lipids (Alabaster, AL, USA) were spiked as internal
standards. The extracted lipids were measured using ABI 3200QT
(Applied Biosystems, Foster City, CA) interfaced to a HPLC
system using multiple reaction-monitoring mode [27]. Phospho-
lipids were separated on a Phenomenex Luna 3 m C18 column
(150 mm62 mm)(Phenomenex, Torrance, CA, USA). Signal
intensities obtained for each lipid class were normalized to the
appropriate internal standard.
Statistical Analysis
Differential levels of lipids or anti-lipid IgGs between time
points were assessed in Prism (GraphPad Software) using the
Wilcoxon nonparametric matched pairs test with a p,0.05 value
considered significant in all cases. A correlation between different
clinical parameters and anti-lipid IgG levels was examined using a
Spearman nonparametric correlation and Linear regression tests.
Results
Total IgG Levels in SLE Patients Remain Unchanged
during Therapy
A reduction in BILAG score was employed as the principal
indicator for treatment success in our SLE patient cohort. We
observed a decrease in this score as patients progressed from flare
through follow-up period (Fig. 1a). Absolute levels of IgG in the
patients’ plasma remain unchanged at these time points (Fig. 1b).
In Table S1, we present BILAG scores for 8 systems: General
(Gen), Mucocutaneous (Muc), Neurological (Cns), Musculoskeletal
(Msk), Cardiovascular and Respiratory (Car), Vasculitis (Vas),
Renal (Ren) and Haematological (Hae). As documented in this
table, BILAG scores in SLE patients at 3-months and 12-months
indicate that these patients have quiescent disease and can thus be
combined as our follow-up cohort.
SLE Patients with Active Disease Exhibit Increased Levels
of Lipid and Anti-lipid Responses
Gas chromatography-mass spectrometry (GC-MS) analyses
indicate significantly higher levels of oxidized cholesterols in
patients during flare versus follow-up. Specifically, 7-b-hydro-
xycholesterol, 7-ketocholesterol (Fig. 2bi, 2ci) were significantly
increased. At the same time, 24S-hydroxycholesterol and 7-a-
hydroxycholesterol levels remained unchanged (Fig. 2ai, 2di).
Only five of the patients had a form of therapy aimed at reducing
cholesterol levels-a combination of fenofibrate, pravastatin or
simvastatin (Table S2). In four out of five patients, administration
of lipid-lowering drugs started from the moment of flare and lasted
over next 12 months. Administration of statins will reduce
cholesterol levels. However, we have not addressed to what extent
statins will affect levels of oxidized cholesterols over time in these
patients. Anti-7-a-hydroxycholesterol IgG responses against oxy-
sterols were significantly higher in patients with flare in
comparison with the results obtained during the follow-up period
(Fig. 2aii). The same trend was seen in anti-7-b-hydroxycholesterol
and anti-7-ketocholesterol IgGs though these differences were not
significant (Fig. 2bii and 2cii). Anti-24S-hydroxycholesterol IgG
levels did not change over time (Fig. 2dii).
Figure 1. SLE disease activity score measured with the BILAG
index reduces significantly over the time while total IgG levels
remain the same. The British Isles Lupus Assessment Group (BILAG)
index score during disease flare and the follow-up period. Figure 1a. A
significant improvement is detectable over the time. Figure 1b. A level
of total IgGs in patients’ blood is similar during disease flares and in the
follow-up period. p,0.05 value considered significant in Wilcoxon test.
doi:10.1371/journal.pone.0055639.g001
Anti-Lipid Responses in SLE
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Figure 2. Levels of oxysterol and anti-oxysterol IgG in SLE patients’ plasma. Analysis by GC-MS and ELISA show higher levels of oxidized
cholesterols or anti-cholesterol IgGs in patients during flare versus follow-up period. Figure 2ai and 2 aii. 7-a-hydroxycholesterol levels and anti-7-a-
hydroxycholesterol IgG levels in plasma. Figure 2bi and 2bii. 7-b-hydroxycholesterol levels and anti-7-b-hydroxycholesterol IgG levels in plasma.
Figure 2ci and 2cii. 7-ketocholesterol levels and anti-7-ketocholesterol IgG levels in plasma. Figure 2di and 2dii. 24S-hydroxycholesterol levels and
anti-24S-hydroxycholesterol IgG levels in plasma. p,0.05 value was considered as significant in Wilcoxon test.
doi:10.1371/journal.pone.0055639.g002
Anti-Lipid Responses in SLE
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Levels of Oxidatively Modified Unsaturated Fatty Acids
and Anti-lipid Antibodies Change during Therapy
Mass-spectroscopy analyses of phosphatidylserine during the
flare and follow-up period suggest a reduction in this lipid over
time (Fig. 3ai). Also, anti-phosphatidylserine IgG levels tend to
increase during the follow-up period (Fig. 3aii).
Normalized values for isoprostanes (normalized against arachi-
donic acid (AA)) significantly decrease from the moment of flare
(Fig. 3bi and 3ci). We employed 15-F2t-IsoP as the antigen in this
assay where we measured anti-isoprostane IgG response (Fig. 3bii).
Anti-15-F2t-IsoP IgG exhibited a trend of higher levels in flare
compared to follow-up.
Anti-lipid IgG Levels for Other Lipids also Change during
Therapy
Lathosterol is a precursor of cholesterol and we detected
significantly higher anti-lathosterol IgG responses in patients with
flare (Fig. 4ai). Phospholipids and anti-phospholipid antibodies are
often seen in autoimmune disorders and are associated with
cerebrovascular disease or moderate-to-severe cognitive dysfunc-
tion. In our study we detected significantly higher levels of anti-
cardiolipin (Fig. 4aii) and anti-oxidized phopsphatidylcholine in
flare (Fig. 4bii). Anti-phopsphatidylcholine IgG in patients with
flare was also increased (Fig. 4bi).
Levels of Anti-lipid Antibodies Negatively Correlate with
BILAG Scores
We analyzed our lipid anti-lipid data for correlations with a
score of disease activity in SLE. For those analyses we included an
additional 7 SLE patients for which we had BILAG scores during
the flare. In total we analyzed 20 patients. Spearman correlation
and linear regression tests showed that anti-24S hydroxycholes-
terol IgG, anti-cardiolipin IgG and anti-phosphatidylserine IgG,
negatively correlate with BILAG score – the disease activity index
(Fig. 5ai, 5aii, 5bi respectively). A similar, although not significant
trend was seen in anti-7-a hydroxycholesterol IgGs (Fig. 5bii). A
higher level of these anti-lipid antibodies was observed in patients
with lower BILAG scores suggesting that these may be markers for
improved prognosis.
Discussion
In SLE, the heterogeneity of disease presentations in patient
populations combined with a poor understanding of the under-
lying pathological mechanisms result in challenges for successful
disease management. The American College of Rheumatology
classification utilizes 11 criteria for diagnosis of lupus, of which a
patient must meet four [28]. Several computerised indices for
measuring clinical disease activity in Systemic Lupus Erythema-
tosus are employed in clinical practice- BILAG, SLEDAI,
LUMINA [29–32]. Despite advances in treatment protocols there
remains a dearth of good diagnostic and prognostic biomarkers to
facilitate improvements in disease characterization and manage-
ment [33–35]. Moreover, the immune modulating treatment used
for SLE remains a significant problem with many patients
developing treatment-associated complications [36]. Thus, the
identification of biomarkers that correlate with a good response to
therapy will have an impact on treatment-associated side-effects
where less-aggressive approaches can be employed [33].
In our lipidomic and immunologic approaches we have
identified a new corpus of biomarkers relevant to this disease.
This study focused on a clinically well-defined SLE cohort that was
monitored over a period of 12 months. Based on clinical score and
statistical tests, we grouped samples provided between 3 and 12
months post-therapy as our follow-up cohort. This approach
enabled us to apply statistical tests for paired samples.
We were also interested in correlations between lipid/anti-lipid
IgG levels and BILAG scores during disease flares. In this case we
did not need paired samples and thus employed 20 samples in
total.
We have identified new targets that correlate with disease score.
Our approach employed gas chromatography-mass spectrometry
(GC-MS) and liquid chromatography-mass spectrometry (LC-MS)
to investigate the lipids of interest. The presence of anti-lipid
autoantibodies was confirmed by an enzyme-linked immunosor-
bent assay where we focused on the immunoglobulin isotype G.
Our high-resolution analysis has identified a cohort of new anti-
lipid autoantibodies. Whilst total IgG levels remain consistent
during therapy, we detected differential levels of anti-lipid IgGs for
four different lipid species: lathosterol; enzymatically produced
oxysterols 7-a-hydroxycholesterol and oxidatively modified phos-
pholipids – cardiolipin, and oxidized phosphatidylcholine.
The measurement of oxygenated cholesterol species remains
technically challenging based on the proposed auto-oxidation that
can occur during lipid derivation, processing or storage from
biological samples. [37–39]. In our study plasma levels of
oxysterols showed a general trend of decrease over time. Thus,
if auto-oxidation occurs, it should happen at a similar level in all
samples tested without a significant influence on absolute ratios.
The main conclusion of this study concerns relationships between
anti-lipid antibodies and BILAG score. Anti-lipid antibodies
identified in lupus patients’ plasma are part of an autoimmune
response that targets lipid antigens. These develop as a result of
pathogenic processes in the afflicted patients. Thus, antibodies
from SLE patient’s plasma should not target oxidized cholesterols
that are result of in vitro auto-oxidation processes (e.g. during the
ELISA plate coating with lipid-antigen). We found similar levels of
anti-24S-hydroxycholesterol IgGs between flare and follow-up
(Fig. 2dii). There was no significant difference in IgG levels against
27-hydroxycholesterol when analyzing the same time points (data
not shown). Phosphatidylserine levels in plasma showed a trend of
reduction over the time. Anti-cardiolipin antibodies are one of
several anti-phospholipid antibodies that have been previously
identified in SLE patients [40] where cardiolipin present on the
surface of apoptotic cells acts as an immunologic trigger for the
production of the autoantibodies [41].
Isoprostanes are generated by the free radical-mediated
peroxidation of arachidonic acid (AA) [42]. 15-F2t-IsoP is a
marker of free radical damage and lipid peroxidation in vivo that is
formed by free radical catalysis of arachidonic acid [43]. Serum
levels of 15-iso-PGF2alpha and 8-iso-PGF2alpha in SLE patients
showed a significantly higher level at flare compared to the post-
therapy period.
BILAG is currently accepted as the best disease activity score in
SLE [22] and thus we analyzed which if any of our lipid/anti-lipid
parameters correlate. We observed that anti-phosphatidylserine,
anti-cardiolipin and anti-24S hydroxycholesterol IgG negatively
correlate with the BILAG score. Anti-7-a-hydroxycholesterol IgGs
also show trend of negative correlation with BILAG score.
However, for this anti-lipid response we were not able to confirm
a statistically significant correlation.
At the same time points we were not able to detect statistically
significant correlations between BILAG scores and one traditional
SLE biomarker - anti-DNA antibodies (data not shown). This can
potentially be explained by the fact that anti-DNA antibodies are
found in only 60% of SLE patients and those antibodies are
particularly associated with lupus nephritis [44].
Anti-Lipid Responses in SLE
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Figure 3. Levels of unsaturated fatty acids and anti-unsaturated fatty acids IgG in SLE patients’ plasma. Figure 3ai and 3aii.
Phosphatidylserine levels and anti-phosphatidylserine IgG levels in plasma. Figure 3bi and 3bii. Isoprostane (15-F2t-IsoP +5-F2t-IsoP) levels normalized
against AA values and anti-15-F2t-IsoP IgG levels in plasma. Figure 3ci. Isoprostane (8-F2t-IsoP) levels normalized against AA values. p,0.05 value was
considered as significant in Wilcoxon test.
doi:10.1371/journal.pone.0055639.g003
Anti-Lipid Responses in SLE
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The negative correlations observed can be explained by two
possible mechanisms: the presence of anti-lipid IgG during flare
may be beneficial and aid immune complex clearance through
IgG receptors expressed on phagocytic cells such as the Kuppfer
cells in the liver [45–46]; or reduced levels of lipids and their
corresponding anti-lipid antibodies in plasma are a consequence of
deposition of immune complexes in the tissues. Both of these
mechanisms are currently under investigation in our laboratory.
It is an interesting observation that levels of anti-lipid IgGs for
24S-hydroxycholesterol and phosphatidylserine remained very
similar over the time period of study. Since levels of these
antibodies negatively correlate with BILAG score at the time of
flare, one explanation could be that their presence during the post-
flare period might have a protective role. For the actual levels of
phosphatidylserine we saw a trend of reduction between flare and
follow-up. This phenomenon suggests that either oxidation
processes in unsaturated fatty acids were reduced or the
development of phosphatidylserine immune complexes intensified
over time.
IgM autoantibodies have been linked to apoptosis-associated
antigen clearance [47–48]. IgM anti-phosphorylcholine was
shown to be notably higher in patients with low SELENA-
SLEDAI disease activity index [47]. Those patients encountered
less cardiovascular and renal problems and high levels of IgM are
attributed to the homeostatic and protective roles [47]. The panel
of auto-antigens that appear during the apoptosis is large and
further identification of protective IgG and IgM antibodies is
required.
Clinical and laboratory markers currently used in SLE have
moderate utility based on specificity and sensitivity. Based on our
findings, we suggest that the measurement of anti-lipid IgGs for
24S-hydroxycholesterol, cardiolipin and phosphatidylserine may
be used as a sensitive and non-invasive method of surveillance
during treatment. These therefore represent improved biomarkers
for the evaluation and development of better therapeutic strategies
aimed at reducing treatment associated morbidity and mortality, a
significant problem in SLE.
Figure 4. Anti-lipid responses against lathosterol, cardiolipin,
phosphatidylcholine and oxidized-phosphatidylcholine. Figure
4ai anti-lathosterol IgG levels in plasma. Figure 4aii anti-cardiolipin IgG
levels in plasma. Figure 4bi anti-phosphatidylcholine IgG levels in
plasma. Figure 4bi anti-oxidized phosphatidylcholine IgG levels in
plasma. p,0.05 value considered significant in Wilcoxon test.
doi:10.1371/journal.pone.0055639.g004
Figure 5. Biomarker candidates that correlate with BILAG scores. Figure 5ai, 5bi, 5ci. Anti-24S hydroxycholesterol IgG, anti-cardiolipin IgG
and anti-phosphatidylserine IgG levels negatively correlate with BILAG scores. Figure 5bii. Anti-7-a-hydroxycholesterol IgG levels also show trend of
negative correlation with BILAG scores. p,0.05 value was considered as significant in Spearman correlation and Linear regression tests.
doi:10.1371/journal.pone.0055639.g005
Anti-Lipid Responses in SLE
PLOS ONE | www.plosone.org 7 February 2013 | Volume 8 | Issue 2 | e55639
Supporting Information
Table S1 BILAG scores summary for three different
time-points. BILAG scores (A-E) for 8 headings: General (Gen),
Mucocutaneous (Muc), Neurological (Cns), Musculoskeletal (Msk),
Cardiovascular and Respiratory (Car), Vasculitis (Vas), Renal
(Ren) and Haematological (Hae). Time point of flare is
represented with 13 patients’ samples (patients C4, C5, C8,
C10, C13, C15, C16, C17, C18, C19, C20, C22 and C24).
Follow-up group consists of patients’ samples from time-point of 3
months (patients C4, C5, C13, C15, C16, C17, C18 and C24) and
time-point of 12 months post treatment (patients C8, C10, C19,
C20 and C22).
(XLS)
Table S2 Statin administration in SLE patients. Five SLE
patients out of thirteen received cholesterol-lowering therapy.
(XLS)
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